Cargando…

Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis

To assess whether the current body of accumulated data can give convincing evidence in favor of sodium-glucose transport protein-2 inhibitor (SGLT-2i) in all types of heart failure (HF). We searched for randomized controlled trials contrasting the effectiveness of SGLT-2i to placebo or other hypogly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiehui, Wang, Lili, Li, Huijun, Huang, Weichao, Huang, Siquan, Zhao, Lingyue, Guo, Wenqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755323/ https://www.ncbi.nlm.nih.gov/pubmed/36531703 http://dx.doi.org/10.3389/fcvm.2022.1067806

Ejemplares similares

Comparative Effectiveness of Complete Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Bayesian Network Meta-Analysis
por: Zhao, Lingyue, et al.
Publicado: (2021)

Corrigendum: Acute Myocardial Infarction Detection Using Deep Learning-Enabled Electrocardiograms
por: Chen, Xiehui, et al.
Publicado: (2021)

Acute Myocardial Infarction Detection Using Deep Learning-Enabled Electrocardiograms
por: Chen, Xiehui, et al.
Publicado: (2021)

Relationship Between the Eosinophil/Monocyte Ratio and Prognosis in Decompensated Heart Failure: A Retrospective Study
por: Chen, Xiehui, et al.
Publicado: (2021)

Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis
por: Chen, Xiuehui, et al.
Publicado: (2023)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
por: Chen, Xiehui, et al.
Publicado: (2021)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Lung ultrasound-guided treatment for heart failure: An updated meta-analysis and trial sequential analysis
por: Li, Yan, et al.
Publicado: (2022)

Association between base excess and mortality in patients with congestive heart failure
por: Guo, Wenqin, et al.
Publicado: (2020)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Yin, Ziwei, et al.
Publicado: (2022)

Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
por: Tornyos, Dániel, et al.
Publicado: (2022)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis
por: Lin, Yanxia, et al.
Publicado: (2022)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Bhalla, Sushen, et al.
Publicado: (2022)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis
por: Guo, Wenqin, et al.
Publicado: (2020)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
por: Yu, Yong-Wei, et al.
Publicado: (2022)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2022)

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
por: Monzo, Luca, et al.
Publicado: (2023)

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease
por: Neijenhuis, Ralph M. L., et al.
Publicado: (2023)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
por: Wang, Yintang, et al.
Publicado: (2022)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2023)

Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature
por: Abdelmasih, Randa, et al.
Publicado: (2021)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
por: Rong, Xi, et al.
Publicado: (2022)

Role of the Gut Microbiota in Glucose Metabolism During Heart Failure
por: Bao, Pei, et al.
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
por: Li, Xuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m9ui3o4837jrnivrvcu4a35odh